[{"abstract": "By buying Alcon shares from Nestl\u00e9, Novartis would raise its stake to 77 percent, and it says it wants to buy the remaining 23 percent.", "web_url": "https://www.nytimes.com/2010/01/05/business/global/05iht-drug.html", "snippet": "By buying Alcon shares from Nestl\u00e9, Novartis would raise its stake to 77 percent, and it says it wants to buy the remaining 23 percent.", "lead_paragraph": "Novartis, the large Swiss drug maker, said Monday that it would take control of the eye care company Alcon by buying a majority stake from Nestl\u00e9 for $28.1 billion. The move would raise its stake in Alcon to 77 percent, and Novartis said it was interested in acquiring the rest of the shares.", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2010/01/05/business/05drug_CA0/thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2010/01/05/business/05drug_CA0/thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "Novartis to Pay $28 Billion for a Majority Stake in Alcon", "kicker": null, "content_kicker": null, "print_headline": "Novartis to Pay $28 Billion for a Majority Stake in Alcon and Wants to Buy the Rest", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Alcon Incorporated", "rank": 2, "major": "N"}, {"name": "subject", "value": "Eyes and Eyesight", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 5, "major": "N"}], "pub_date": "2010-01-05T01:54:34+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "Global Business", "byline": {"original": "By Chris V. Nicholson", "person": [{"firstname": "Chris", "middlename": "V.", "lastname": "Nicholson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/9844d5f3-ac80-5ce8-9bf5-27a727066390", "word_count": 718, "uri": "nyt://article/9844d5f3-ac80-5ce8-9bf5-27a727066390"}, {"abstract": "An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying the Swiss drug maker is trying to circumvent protections for minority shareholders.", "web_url": "https://dealbook.nytimes.com/2010/01/05/alcon-directors-criticize-novartis-tactics/", "snippet": "An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying the Swiss drug maker is trying to circumvent protections for minority shareholders.", "lead_paragraph": "An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying Novartis, the Swiss drug maker, is trying to circumvent protections for minority shareholders.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Alcon Directors Criticize Novartis Tactics", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Alcon Incorporated", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 4, "major": "N"}, {"name": "glocations", "value": "Switzerland", "rank": 5, "major": "N"}], "pub_date": "2010-01-05T10:52:18+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/43a4966c-ca10-5890-8df5-74322804b5c9", "word_count": 334, "uri": "nyt://article/43a4966c-ca10-5890-8df5-74322804b5c9"}]